Belfort PLF, Tadeu VR, Fortes BBVAC

Language: Portugués
References: 10
Page: 52-54
PDF size: 373.15 Kb.

ABSTRACT

Psoriasis is a chronic inflammatory disease characterized by epidermal hyperplasia mediated by T lymphocytes. It is known that one of the key cytokines involved in the pathogenesis of the disease is tumor necrosis factor (TNF-α) and several treatments currently proposed have in common the phenomenon of tachyphylaxis. Being pentoxifylline able to antagonize the production and activity of TNF alpha, two cases of psoriasis refractory to conventional treatments are described, in which pentoxifylline was introduced and there was a significative reduction in PASI.

REFERENCES

1. Tanetsakunwatana T, Tovanabutra N, Kanchanarattanakorn K, Chiewchanvit S. Pentoxifylline as add-on therapy in the treatment of moderate to severe psoriasis. Chiang Mai Med J. 2013; 52 (3-4): 43-50.

2. Çakmak SK, Çakmak A, Gönül M, Kiliç A, Gül Ü. Pentoxifylline use in dermatology. Inflamm Allergy Drug Targets. 2012; 11 (6): 422-432.

3. Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Dovepress. 2016; 6: 93-104.

4. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol. 2008; 181 (7): 4733-4741.

5. Hassan I, Dorjay K, Anwar P. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014; 5 (4): 510-516.

6. Arruda LHF, Campbell GAM, Takahashi MDF. Psoriasis. An Bras Dermatol. 2001; 76: 141-167.

7. Magalhães GM. Psoríase e pentoxifilina: ensaio clínico duplo cego, randomizado e controlado - avaliação clínica, histopatológica e imunohistoquímica. An Bras Dermatol. 2005; 80 (4).

8. Magela-Magalhães G, Coelho da Silva Carneiro S, Peisino do Amaral K, de Freire-Cássia F, Machado-Pinto J, Cuzzi T. Psoriasis and pentoxifylline: a clinical, histopathologic, and immunohistochemical evaluation. Skinmed. 2006; 5 (6): 278-284.

9. Carneiro SC, Medeiros R, Magalhães GM, Alves C, Cuzzi T, Sotto MN. Ação da pentoxifilina nos dendrócitos dérmicos FXIIIa de placas de psoríase. An Bras Dermatol. 2005; 80 (Suppl 3): S314-S322.

10. el-Mofty M, el-Darouti M, Rasheed H, Bassiouny DA, Abdel-Halim M, Zaki NS et al. Sulfasalazine and pentoxifylline in psoriasis: a possible safe alternative. J Dermatolog Treat. 2011; 22 (1): 31-37.